GlomCon Hawaii 2026 Abstracts

period, with an 8-week safety follow-up.The key secondary endpoint was the annualized slope (from week 4) of estimated glomerular filtration rate (eGFR) over 24 months.Secondary endpoints included change in eGFR from baseline at 24 months and safety.A post hoc analysis evaluated annualized eGFR slope from baseline through 24 months.Results In total, 510 patients were randomized (sibeprenlimab, n = 259; placebo, n = 251).The annualized eGFR slope estimated over 24 months was 0.3 mL/min/1.73m 2 / yr (95% CI, -0.4 to 0.9) with sibeprenlimab and -4.2 mL/min/1.73m 2 /yr (95% CI, -4.9 to -3.6) with placebo (treatment difference: 4.5 mL/min/1.73m 2 /yr; 95% CI, 3.6 to 5.4; P < 0.0001).The least-squares mean treatment difference for eGFR change from baseline was 9.2 mL/ min/1.73m 2 (95% CI, 7.1 to 11.4; P < 0.0001).Post hoc analysis of annualized eGFR slope estimated from baseline demonstrated a treatment difference of 4.7 mL/min/1.73m 2 /yr (95% CI, 3.8 to 5.6).Sibeprenlimab was well tolerated, with safety comparable to placebo, consistent with previously communicated interim results.Conclusions Sibeprenlimab stabilized kidney function over 24 months with a favorable safety profile.